PURPOSE: Patients who suffer from non–small-cell lung cancer (NSCLC) with ipsilateral
mediastinal lymph node involvement (N2) belong to a heterogeneous subgroup of patients …

Therapeutic strategy in advanced stage disease remains controversial. Theoretically
resectable, Stage IIIa disease includes a high proportion of non‐resectable nodal diseases …

Risks of secondary lung cancer in patients with non-small cell lung cancer and small cell
lung cancer are estimated to be 1–2% and 2–10% per patient per year, respectively …

Of all newly diagnosed cases of lung cancer approximately 80% are non–small cell lung
cancer (NSCLC). Unfortunately, over half have extrapulmonary spread at diagnosis …

Spezifität und Sensitivität serologischer Tumormarker (neuronspezifische Enolase [NSE]
beim kleinzelligen Bronchialkarzinom, karzinoembryonales Antigen [CEA] und CYFRA 21-2 …

Twenty to 30% of patients with non-small-cell lung cancer (NSCLC) in stage III are not
resectable primarily with 5-year survival less than 10%. Since the majority of patients die …

Locally advanced non‐small cell lung cancer (NSCLC) is, in fact, a systemic disease
requiring a multimodality approach for optimal treatment. The role of preoperative …

Combined modality treatment of patients with stage III non–small-cell lung cancer (NSCLC)
has recently become widely accepted. Standard combinations are neoadjuvant …

A recent meta-analysis and randomized studies have demonstrated that combined
chemoradiotherapy is associated with a survival advantage for selected patients with locally …

Lung cancer currently represents one of the most common malignancies among men and
women in different European countries [1]. It is characterised by an extremely poor …